Literature DB >> 27456677

Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B).

Richard Bell1, Sanjay Pandanaboyana2, J Peter A Lodge1, K Raj Prasad1, Rebecca Jones3, Ernest Hidalgo4.   

Abstract

AIM: This study aims to report the outcomes following primary liver resection (PLR) in patients with cirrhosis including stratification according to the Barcelona Clinic Liver Cancer (BCLC) classification.
METHODS: Patients with cirrhosis and hepatocellular carcinoma (HCC) who had PLR between 2000 and 2013 were examined. Overall survival (OS), disease-free survival (DFS) and recurrence rate (RR) were analysed. Management after recurrence was reviewed as well as comparison to a series of 116 patients listed directly for liver transplant.
RESULTS: Seventy-one patients underwent PLR. Median follow-up was 40 months. The 1-, 3- and 5-year OS and DFS for the series were 77, 69 and 61 % and 69, 39 and 28 % respectively. Overall recurrence was 59 % (44/71) and only 36 % (15/44) of those patients had a further potentially curative procedure. The 1-3-5-year OS and DFS in the BCLC-A (44 patients) were 86, 78 and 68 % and 78, 48 and 44 % respectively. The RR in BCLC-A was 45 % (20 patients) with half (11 patients) suitable for further treatment with curative intent. The 1-3-5-year OS and DFS in the BCLC-B (17 patients) were 81, 74 and 60 % and 58, 29 and 7 % respectively. The overall RR in BCLC-B was 76 % (13 patients).
CONCLUSION: Recurrence following PLR for HCC in patients with cirrhosis is high with only a third of patients suitable for further potentially curative procedures. For patients with BCLC-A (or within Milan criteria), PLR provided a 68 % 5-year OS with 44 % of them free of disease. Surgery can offer satisfactory OS in carefully selected patients in the BCLC-B stage.

Entities:  

Keywords:  BCLC; HCC; Liver transplant; Primary liver resection

Mesh:

Year:  2016        PMID: 27456677     DOI: 10.1007/s00423-016-1475-3

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  27 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 2.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  Comparison between observed survival after resection of transplantable hepatocellular carcinoma and predicted survival after listing through a Markov model simulation.

Authors:  Alessandro Cucchetti; Matteo Cescon; Giorgio Ercolani; Maria Cristina Morelli; Massimo Del Gaudio; Matteo Zanello; Antonio Daniele Pinna
Journal:  Transpl Int       Date:  2011-05-26       Impact factor: 3.782

5.  Resection of hepatocellular carcinoma in patients with cirrhosis.

Authors:  J Balsells; R Charco; J L Lazaro; E Murio; V Vargas; E Allende; C Margarit
Journal:  Br J Surg       Date:  1996-06       Impact factor: 6.939

6.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

7.  Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

Authors:  J M Llovet; J Fuster; J Bruix
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

8.  When to perform hepatic resection for intermediate-stage hepatocellular carcinoma.

Authors:  Alessandro Cucchetti; Benjamin Djulbegovic; Athanasios Tsalatsanis; Alessandro Vitale; Iztok Hozo; Fabio Piscaglia; Matteo Cescon; Giorgio Ercolani; Francesco Tuci; Umberto Cillo; Antonio Daniele Pinna
Journal:  Hepatology       Date:  2015-01-23       Impact factor: 17.425

9.  Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma.

Authors:  Rey-Heng Hu; Ming-Chi Ho; Yao-Ming Wu; Seng-Chang Yu; Po-Huang Lee
Journal:  Clin Transplant       Date:  2005-04       Impact factor: 2.863

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  3 in total

1.  Effect of KI-67 positive cellular index on prognosis after hepatectomy in Barcelona Clinic Liver Cancer stage A and B hepatocellular carcinoma with microvascular invasion.

Authors:  Hong-Hao Li; Lu-Nan Qi; Liang Ma; Zu-Shun Chen; Bang-De Xiang; Le-Qun Li
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

2.  New Hepatic Resection Criteria for Intermediate-Stage Hepatocellular Carcinoma Can Improve Long-Term Survival: A Retrospective, Multicenter Collaborative Study.

Authors:  Hiroya Iida; Masaki Kaibori; Fumitoshi Hirokawa; Yoshihiro Inoue; Masaki Ueno; Kousuke Matsui; Morihiko Ishizaki; Shogo Tanaka; Shigekazu Takemura; Takeo Nomi; Daisuke Hokutou; Takehiro Noda; Hidetoshi Eguchi; Takuya Nakai; Hiromitsu Maehira; Haruki Mori; Masaji Tani; Shoji Kubo
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01

3.  Comparison of the effect on the prognosis of HCC in terms of different surgical approaches for hepatic inflow occlusion.

Authors:  Hong-Hao Li; Liang Ma; Bang-De Xiang; Lu-Nan Qi; Le-Qun Li
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.